Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522280 | 1.00 | MAPT (0.53) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6512879 | 0.93 | MAPT (0.56) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6512365 | 0.93 | MAPT (0.56) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6512792 | 0.92 | HDAC3 (0.46) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6515164 | 0.92 | HDAC3 (0.46) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6512798 | 0.92 | HDAC3 (0.46) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6511419 | 0.91 | SMN1; SMN2 (0.46) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6522323 | 0.91 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6520118 | 0.91 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2HTTLMNATP53 | |
| SCHEMBL6519188 | 0.91 | SMN1; SMN2 (0.46) | MAPTSMN1; SMN2HTTLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-6794406-B2 | FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1347959-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030078288-A1 | Indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | US | disclosed |
| EP-0975220-B1 | USE OF SULFONYLOXADIAZOLONES AS MICROBICIDES | BAYER CROPSCIENCE AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2002051805-A1 | INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078288-A1 | Indole derivatives | IDO1, IDO2, TPH2 | MAPT 839/4885SMN1; SMN2 4749/4885HTT 399/4885 |
| US-20050032874-A1 | Anticholesterol agents; arteriosclerosis | HMGCR, CYP46A1, EBP | MAPT 3453/4885SMN1; SMN2 4875/4885HTT 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.